The vaccine will help prevent millions of patients who are at risk of acquiring the vector-borne disease, the release said, adding that company's phase III efficacy clinical study programme for its dengue vaccine candidate was conducted in over 31,000 participants across 10 endemic countries in Asia and Latin America. "We plan to submit the vaccine for licensure in 2015 in endemic countries where dengue is a public health priority," President and CEO, Sanofi Pasteur, Olivier Charmeil said. Country Head, Sanofi Pasteur, Dr Stephan Barth said dengue is a serious health concern in India, causing a significant but under-reported burden.